Oxford BioMedica and MolMed have announced a licence agreement for Oxford BioMedica's retroviral ex vivo gene delivery technology
The agreement provides MolMed with rights to utilise this technology in the development of MolMed's product pipeline.
Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments.
In addition, Oxford BioMedica will receive payments on the achievement of clinical and regulatory milestones by MolMed and product royalties.
The retroviral ex vivo gene delivery technology combines Oxford BioMedica's technology with some of the gene therapy technology acquired from Chiron in 2004 Oxford BioMedica's CEO, professor Alan Kingsman, said: "We are delighted to welcome MolMed to the list of Oxford BioMedica's technology licensees".
"This agreement provides further evidence of the breadth and strength of our proprietary gene delivery technology."
